On April 21, 2023, Gary A. Lyons informed the Company that he will resign from the Board of Directors on the date of the Company’s 2023 annual meeting of stockholders, because of overboarding concerns under proxy advisor and other institutional investor policies.
Key facts
Extracted from this filing and checked against the source text.
Fresh Tracks Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
Exchange
nasdaq
Notice
deficiency notice
Deficiency
minimum bid price
Rules
5550(a)(2)
Exact text from the filing
April 24, 2023, Fresh Tracks Therapeutics, Inc. (the “Company”) received a notice from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 per share for 30 consecutive business days, the Company does not comply with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Rule”). The notification has no immediate effect on the listing of the Company’s comm
Gary A. Lyons departed as Director at Fresh Tracks Therapeutics, Inc..
Action
resign
Role
Director
Exact text from the filing
On April 21, 2023, Gary A. Lyons informed the Company that he will resign from the Board of Directors on the date of the Company’s 2023 annual meeting of stockholders, because of overboarding concerns under proxy advisor and other institutional investor policies.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.